Back to results
US 12,528,847 B2Granted
Heterodimeric inactivatable chimeric antigen receptors
AssigneesLudwig Institute for Cancer Research, Ecole Polytechnique Federale de Lausanne
InventorsGeorge Coukos, Melita Irving, Bruno Correia, Pablo Gainza-Cirauqui, Greta Maria Paola Giordano Attianese
Life of this patent
Estimating the term…
Abstract
The invention relates to heterodimeric inactivatable chimeric antigen receptors (CARs) and their use for treatment.
Claims25
A heterodimeric inactivatable chimeric antigen receptor (CAR) comprising:
- a) a first polypeptide chain comprising:
- i) an extracellular region;
- ii) a first transmembrane (TM) region;
- iii) a first co-stimulatory endodomain (ED);
- and
- iv) a first member of a dimerization pair;
- and
- b) a second polypeptide chain comprising:
- i) optionally, an extracellular region which does not comprise a target-binding region;
- ii) a second TM region;
- iii) optionally, a second co-stimulatory ED;
- iv) a second member of the dimerization pair;
- and
- v) an intracellular signaling ED,
- wherein the first and second member of the dimerization pair form a heterodimer, wherein the heterodimer formed by the first and second member of the dimerization pair is disrupted in the presence of an inhibitory molecule resulting in inhibition of CAR-mediated signaling, and wherein (1) the first member of the dimerization pair comprises a sequence selected from SEQ ID NO:
- 5, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 24 comprising residues 35-50 of SEQ ID NO:
- 22 in place of residues 51-91 of SEQ ID NO:
- 24, and SEQ ID NO:
- 30, and the second member of the dimerization pair comprises a sequence IAXXLXXIGXXF (SEQ ID NO:
- 179), wherein X is any natural amino acid and L is optionally substituted with A, or (2) the first member of the dimerization pair comprises a sequence IAXXLXXIGXXF (SEQ ID NO:
- 179), wherein X is any natural amino acid and L is optionally substituted with A, and the second member of the dimerization pair comprises a sequence selected from SEQ ID NO:
- 5, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 24 comprising residues 35-50 of SEQ ID NO:
- 22 in place of residues 51-91 of SEQ ID NO:
- 24, and SEQ ID NO:
- 30, and
- the inhibitory molecule is venetoclax, A-1331852, or A-1155463.
31 more elements
Dependencies are inferred from the claim text.